The capital injection allows Remedium Bio to accelerate its Prometheus platform, a gene therapy technology designed to turn adipocytes into durable sites for therapeutic protein production. By enabling long-lasting, adjustable dosing through minimally invasive subcutaneous administration, the company aims to replace traditional, frequent protein injections for patients suffering from cardiometabolic, immunological, and neurological conditions.
In section Releases
Remedium Bio Secures $10 Million to Advance Gene Therapy Platform
A $10 million Series A financing round led by Lifespan Vision Ventures will propel Remedium Bio toward its first human clinical trials. The investment, which includes contributions from Eli Lilly and Company and HKX Capital, targets the expansion of the biotech firm's proprietary protein therapeutics platform for chronic disease management.
As part of the financing agreement, Harry Robb of Lifespan Vision Ventures joins the Remedium board. Andrew Worden, founding partner at Lifespan, noted that the platform addresses critical shortcomings in current biologic therapies, while Remedium CEO Frank Luppino emphasized the firm's focus on scaling its pipeline toward clinical readiness. The company remains committed to proving its technology's efficacy as a cost-effective alternative to standard chronic care treatments.
Comments (0)
No comments yet. Be the first!